Caroline McCoach

MD PhD

Thoracic oncologist
Bench-to-bedside researcher

About me

Dr. Caroline McCoach is a thoracic oncologist who specializes in treating adults with lung and other chest cancers. She personalizes her treatment approach based on the cancer type in combination with an individual patient's goals.

McCoach's research focuses on integrating clinical findings with laboratory studies to improve patient care. Her work includes developing new drug therapies for lung cancers. Also, by investigating how cancer can become resistant to targeted therapies, her research aims to help create therapies that may delay or prevent cancer cell resistance to treatment.

McCoach earned a doctorate in biochemistry from Stanford University before earning her medical degree at the University of Colorado. She completed her residency training in internal medicine at the University of California, Davis, where she was chief resident in her final year. She then completed a research fellowship at UC Davis, where she focused on developing clinical trials for lung cancer therapies, before returning to the University of Colorado for a clinical fellowship in hematology and oncology, which concentrated on thoracic malignancies with gene mutations.

McCoach is a member of the American Society of Clinical Oncology and American Society of Hematology.

  • Education

    University of Colorado School of Medicine, 2009

    Stanford University, Ph.D., Biochemistry, 2005

  • Residencies

    UC Davis, Internal Medicine, 2013

  • Fellowships

    UC Davis, Medical Oncology, 2014

    University of Colorado School of Medicine, Hematology and Oncology, 2017

  • Academic Title

    Assistant Professor

I am dedicated to research that will ultimately improve treatment options for my patients.

Thoracic Surgery and Oncology Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth St., Sixth Floor
San Francisco, CA 94158

Decorative Caduceus

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-s...

Will be measured by evaluating the number and frequency of adverse events as determined by the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version (v)5.0 by investigator's assessment and to de...

Recruiting

Decorative Caduceus

Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid T...

Incidence rate and category of dose limiting toxicities (DLTs) during the first 28-day cycle of LOXO-292 (selpercatinib) treatment

Recruiting

Decorative Caduceus

Dose-Escalation and Dose-Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tum...

Incidence, nature, and severity of treatment-emergent AEs and SAEs, graded according to the NCI CTCAE v5 for the combination of RMC-4360 and cobimetinib

Recruiting

Decorative Caduceus

Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

Incidence, nature, and severity of treatment-emergent AEs and serious AEs, including incidence and severity of findings in laboratory values and vital signs for RMC-4630 monotherapy

Recruiting

Share